Facebook Twitter LinkedIn Google Plus RSS

Celegene gets FDA approval for Revlimid

By ,

Celgene Corp. on Wednesday announced it won Food and Drug Administration approval for Revlimid, a treatment for certain patients with mantle cell lymphoma.

According to a news release from Celgene, in Summit, the drug is approved for patients whose disease has relapsed or progressed after two prior therapies.

Also Popular on NJBIZ

Write to the Editorial Department at editorial@njbiz.com

Related Stories

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy